Drug intelligence / Profile preview

ABT-614

Development stage: Phase 1
Lead developer: Abbott
Modality: Small Molecules
Administration: Oral

Overview

ABT-614 is a small molecule drug developed by Abbott Laboratories as a selective antagonist of the dopamine D3 receptor. It was investigated primarily for its potential therapeutic effects in metabolic and renal diseases, including type 2 diabetes with chronic kidney disease and albuminuria. The mechanism of action involves antagonism at the dopamine D3 receptor, which is implicated in various neuroendocrine and renal pathways. Clinical development reached Phase 1 trials, focusing on safety, tolerability, pharmacokinetics, and effects on glomerular filtration rate in patients with type 2 diabetes and chronic kidney disease[1][3][4].

Other names: ABT-614ABT614ABT 614

Targets

DRD3 (Dopamine receptor D3)

Beyond the preview

Go deeper on ABT-614.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABT-614.

Explore the full profile